Ampersand Capital Partners has closed AMP-26 at its $1.5 billion hard cap less than five months after launch.
The oversubscribed vehicle represents the firm’s twelfth primary fund since 1992. The fundraise provides additional capital to support Ampersand’s strategy of investing in healthcare and life sciences businesses that provide mission-critical products and services to the innovation ecosystem.
AMP-26 will continue Ampersand’s focus on partnering with founders and management teams through both majority and minority investments. The firm targets companies generating approximately $10 million to $200 million in revenue with positive Ebitda, seeking to help management teams accelerate growth and build businesses across its core healthcare sectors.